[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366538-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366538-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","new-histopathological-and-molecular-findings-in-gynecological-cancers-review","New histopathological and molecular findings in gynecological cancers - review","","This review summarizes key advances in the pathological classification of gynecological tumors, emphasizing recent updates and major changes linked to the 2020 WHO Classification. Coverage includes TCGA-based molecular classification of endometrial carcinomas, guidance for incorporating findings into routine reporting, and clinical-pathologic relationships such as synchronous endometrial and ovarian endometrioid carcinomas. It also addresses lymphovascular space invasion, HPV-associated versus HPV-independent cervical and vulval/vaginal cancer categories, and newly described tumor entities with defining molecular alterations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/new-histopathological-and-molecular-findings-in-gynecological-cancers-review/366538/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/new-histopathological-and-molecular-findings-in-gynecological-cancers-review/366538.png","ImageObject",300,407,{"name":42,"@type":43},"Jasmine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the review focus on regarding gynecological cancer classification?","Question",{"text":63,"@type":64},"It focuses on significant developments and major changes in the pathological classification of gynecological cancers, including those connected to the 2020 WHO Classification.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is TCGA used in the review for endometrial carcinoma?",{"text":68,"@type":64},"It describes the TCGA molecular classification of endometrial carcinomas and discusses how to integrate TCGA concepts into routine reporting.",{"name":70,"@type":61,"acceptedAnswer":71},"Which molecular types of endometrial carcinoma are highlighted by TCGA?",{"text":72,"@type":64},"The review highlights four intrinsic molecular types: POLE mutated/ultramutated, mismatch repair deficient/MSI-H/hypermutated, p53 abnormal/copy number high, and copy number low/no specific molecular profile (NSMP).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366538,1790196654,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","DOI: 10. 1002/ijgo.70283  \nS U PPL E M E NT A RT I C L E  \nNew histopathological and molecular findings in gynecological cancers  \nW. Glenn McCluggage  \nDepartment of Pathology, Belfast Health and Social Care Trust, Belfast, UK  \nCorrespondence  \nW. Glenn McCluggage, Department of Pathology, Belfast Health and Social Care Trust, Grosvenor Road, Belfast BT12 6BA, UK.  \nEmail: glenn. mccluggage@belfasttrust. [hscni. net](hscni. net)  \nAbstract  \nThis review covers significant developments in the pathological classification of gynecological tumors in recent years. Topics covered include The Cancer Genome Atlas (TCGA) Classification of endometrial carcinomas and how to incorporate this into routine reporting, the fact that most synchronous endometrial and ovarian endometrioid carcinomas represent metastasis from the endometrium to the ovary, and the important subject of lymphovascular space invasion in endometrial carcinomas. The categorization of cervical squamous cell carcinomas (SCCs) and adenocarcinomasand vulval and vaginal SCCs into prognostically meaningful HPV-associated and HPVindependent types is also discussed. Some “newly” described tumor types are covered, including endometrial and ovarian mesonephric-like adenocarcinomas, STK11 adnexal tumors, and a number of uterine mesenchymal neoplasms associated with specific molecular abnormalities. Important molecular events in ovarian sex cord–stromal tumors and other rare adnexal neoplasms are also discussed.  \nK E Y WO R D S  \ncervix, endometrium, female genital tract, gynecological cancer, pathology, tubo-ovarian, vagina, vulva  \n1 | INTRODUCTION  \nThe 2020 WHO Classification of Female Genital Tract Tumors (5th edition) was published online and in the traditional “Blue Book” in 2020.1 Currently, this Classification is being updated and the sixth edition is expected to be published in 2026. This review covers significant recent developments and major changes in the classification of gynecological cancers, some of which emanate from the 2020 WHO Classification and a few others that have followed. Most of the topics discussed herein cannot be covered in detail and the reader is referred to the key references provided. New technologies, such as single-cell technologies, liquid biopsies, ascitic fluid profiling, molecular cytopathology, and artificial intelligence, are likely to play an increasing role but these are not discussed in this review.  \n2 | THE CANCER GENOME ATLAS ( TC GA ) MOLECULAR CLASSIFICATION OF ENDOMETRIAL CARCINOMAS  \nAs early as 1983, Bokhman proposed that there were two types of endometrial carcinoma, type I and type II.2 Broadly speaking, type I carcinomas (prototypically endometrioid-type) arise in perimenopausal or early postmenopausal women, are low-grade, typically early-stage neoplasms arising on a background of atypical hyperplasia and are positive with hormone receptors. Type II carcinomas (prototypically serous-type) arise in elderly postmenopausal women, are high-grade, typically advanced-stage neoplasms arising in atrophic endometrium, and are negative with hormone receptors. However, although useful as a broad concept, it was always clear that there is  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s) . International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.  \nInt J Gynecol Obstet. 2025;171(Suppl. 1):109–[119.](119. wileyonlinelibrary.com/journal/ijgo | 109)[ wileyonlinelibrary.com/journal/ijgo](119. wileyonlinelibrary.com/journal/ijgo | 109)[ |](119. wileyonlinelibrary.com/journal/ijgo | 109)[ 109](119. wileyonlinelibrary.com/journal/ijgo | 109)  \n110  \n McCLUGGAGE  \nsignificant overlap in the clinical and pathological features in many individual tumors and the Bokhman classifi","cbCais6t9Iw41Pi6","https://ap.wps.com/l/cbCais6t9Iw41Pi6","pdf",2055334,11,"English","# Introduction\n# The Cancer Genome Atlas (TCGA) molecular classification of endometrial carcinomas\n## Background: Bokhman classification and its limitations\n## 2020 WHO morphology-based classification and interobserver variation\n## TCGA discovery of four intrinsic molecular types","[{\"question\":\"What does the review focus on regarding gynecological cancer classification?\",\"answer\":\"It focuses on significant developments and major changes in the pathological classification of gynecological cancers, including those connected to the 2020 WHO Classification.\"},{\"question\":\"How is TCGA used in the review for endometrial carcinoma?\",\"answer\":\"It describes the TCGA molecular classification of endometrial carcinomas and discusses how to integrate TCGA concepts into routine reporting.\"},{\"question\":\"Which molecular types of endometrial carcinoma are highlighted by TCGA?\",\"answer\":\"The review highlights four intrinsic molecular types: POLE mutated/ultramutated, mismatch repair deficient/MSI-H/hypermutated, p53 abnormal/copy number high, and copy number low/no specific molecular profile (NSMP).\"}]","New histopathological and molecular findings in gynecological cancers - review | PDF",1790166015,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e317bbacdacfe113455ff8c03c68f24e.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a63937c0a96c6694cd71b2afee032ea1.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff78bd7aa5cd2a260892f04470b12b23.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e5e2a7a4762742fa4d34effe41786d3.webp",980,1287]